William Blair Comments on Pyxis Oncology Q1 Earnings

Pyxis Oncology, Inc. (NASDAQ:PYXS) – Analysts at William Blair issued their Q1 2025 earnings per share estimates for shares of Pyxis Oncology in a report issued on Tuesday, March 18th. William Blair analyst A. Hsieh expects that the company will post earnings of ($0.32) per share for the quarter. William Blair has a “Market Perform” rating on the stock. The consensus estimate for Pyxis Oncology’s current full-year earnings is ($1.04) per share. William Blair also issued estimates for Pyxis Oncology’s Q2 2025 earnings at ($0.32) EPS, Q3 2025 earnings at ($0.31) EPS, Q4 2025 earnings at ($0.31) EPS, FY2025 earnings at ($1.26) EPS and FY2026 earnings at ($1.32) EPS.

Several other research firms also recently weighed in on PYXS. Royal Bank of Canada reissued an “outperform” rating and set a $8.00 target price on shares of Pyxis Oncology in a research report on Wednesday. HC Wainwright reissued a “buy” rating and set a $5.00 target price on shares of Pyxis Oncology in a research report on Wednesday. One research analyst has rated the stock with a hold rating and five have given a buy rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $9.20.

Pyxis Oncology Stock Performance

NASDAQ PYXS opened at $1.12 on Friday. The company has a market cap of $66.60 million, a P/E ratio of -1.09 and a beta of 1.11. The business’s 50 day moving average price is $1.33 and its 200-day moving average price is $2.38. Pyxis Oncology has a fifty-two week low of $0.99 and a fifty-two week high of $6.18.

Pyxis Oncology (NASDAQ:PYXS) last released its quarterly earnings data on Tuesday, March 18th. The company reported ($0.32) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.33) by $0.01.

Hedge Funds Weigh In On Pyxis Oncology

Several hedge funds have recently bought and sold shares of PYXS. LMR Partners LLP bought a new position in Pyxis Oncology in the 3rd quarter valued at $294,000. Intech Investment Management LLC bought a new position in Pyxis Oncology in the 3rd quarter valued at $55,000. MetLife Investment Management LLC grew its position in Pyxis Oncology by 41.1% in the 3rd quarter. MetLife Investment Management LLC now owns 18,818 shares of the company’s stock valued at $69,000 after acquiring an additional 5,484 shares during the last quarter. Jacobs Levy Equity Management Inc. bought a new position in Pyxis Oncology in the 3rd quarter valued at $1,405,000. Finally, State Street Corp grew its position in Pyxis Oncology by 28.0% in the 3rd quarter. State Street Corp now owns 951,251 shares of the company’s stock valued at $3,491,000 after acquiring an additional 208,344 shares during the last quarter. Institutional investors own 39.09% of the company’s stock.

About Pyxis Oncology

Pyxis Oncology, Inc, a clinical stage company, engages in the development of therapeutics to treat cancers. Its lead antibody-drug conjugates (ADC) product candidate is PYX-201, an investigational novel ADC consisting of human immunoglobulin G1 (IgG1), which is in Phase 1 clinical trial to treat patients with relapsed or refractory solid tumors; and lead immuno-oncology (IO) product candidate is PYX-106, an investigational fully human IgG1 Siglec-15-targeting antibody that is in Phase 1 clinical trial to treat patients with advanced solid tumors.